Great news from the 2013 AASLD Liver Meeting regarding a new, lower-dose formulation of Tenofovir for the treatment of hepatitis B
From HIVandHepatitis.com
Published Thursday, 21 November 2013 00:00Written by Liz Highleyman
A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC. Continue reading "Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity"